logo
Energy giant SSE sees UK dry spell hit water power generation

Energy giant SSE sees UK dry spell hit water power generation

The Perth-based energy giant reported a 4% decrease in output in May and June, compared with the same period last year.
This was due to 'unfavourable weather conditions' affecting its hydro power stations, which work by harnessing the power of moving water to generate electricity.
SSE's hydro generation dropped by about 40% in the three months to June, compared with the same period a year ago.
Scotland has experienced a lack of rainfall, with regions in the east seeing the driest spring since 1964, according to the Scottish Environment Protection Agency.
SSE told investors that the dry conditions offset strong operational availability across its renewable power plants.
Meanwhile, the company welcomed 'clarity' from the Government's decision not to split the country into different energy pricing zones.
Energy Secretary Ed Miliband confirmed earlier this month that the UK would retain a single national wholesale price for electricity but reform the current system.
SSE said in a statement to investors that the decision brings 'welcome clarity for both investors and consumers whilst sending a strong investment signal that reaffirms the UK as a world-leading renewables market'.
The form said its financial outlook for the year continues to be subject to weather, market conditions and plant availability, with the key winter months still to come.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Apple cites Supreme Court's birthright ruling in fight over Epic Games injunction
Apple cites Supreme Court's birthright ruling in fight over Epic Games injunction

Reuters

time2 minutes ago

  • Reuters

Apple cites Supreme Court's birthright ruling in fight over Epic Games injunction

July 23 (Reuters) - Apple (AAPL.O), opens new tab is hoping a new U.S. Supreme Court ruling curbing the power of federal judges to issue nationwide orders will help the technology giant win an appeal in a lawsuit requiring it to revamp its lucrative App Store. In a court filing, opens new tab on Tuesday, Apple told the San Francisco-based 9th U.S. Circuit Court of Appeals that the Supreme Court's June order in a case involving birthright citizenship bolsters the iPhone maker's arguments in a high-stakes standoff with 'Fortnite' game developer Epic Games. The Supreme Court limited when judges can issue so-called universal injunctions that apply broadly, and not just to the parties in a lawsuit. The justices did not rule on whether the Trump administration can legally terminate the right to citizenship for people born on U.S. soil, but the decision was a win for the administration, which had complained about individual lower courts blocking its policies nationwide. Even though the case at the high court had nothing to do with Apple, its appeal could test the scope of the justices' ruling. Apple and Epic did not immediately respond to requests for comment. Apple in its appeal is challenging a U.S. district judge's order in April that said the company must open its App Store to more competition, allowing all developers — not just Epic — more freedom to steer consumers to alternative payment options outside of an app. The appeal also challenges the judge's finding that Apple was in contempt for violating a prior injunction in the same case. Epic Games sued Apple in 2020 to loosen its control over transactions in applications that use its iOS operating system and how apps are distributed to consumers. U.S. District Judge Yvonne Gonzalez Rogers in 2021 said Apple must allow developers to more easily steer consumers to potentially cheaper non-Apple payment options. Apple defied that court order to maintain a revenue stream worth billions of dollars, Gonzalez Rogers ruled in April. Apple has denied any wrongdoing, and defended its compliance with the court's orders. Apple told the 9th Circuit that, after the Supreme Court's birthright citizenship decision, judges no longer have freestanding authority to issue universal injunctions. Apple also noted that Epic pursued its lawsuit on its own, not as a class action on behalf of a larger group. Epic told the appeals court in May that Apple's App Store changes will have wide-reaching benefits for the industry and consumers. 'The sky has not fallen. Instead, developers and consumers are finally beginning to see the long-awaited benefits of increased competition,' Epic said. The case is Epic Games Inc v. Apple Inc, 9th U.S. Circuit Court of Appeals, No. 25-2935. For Epic: Gary Bornstein and Yonatan Even of Cravath, Swaine & Moore For Apple: Gregory Garre and Roman Martinez of Latham & Watkins Read more: Apple, Visa and Mastercard win dismissal of merchant antitrust lawsuit over payment fees Epic Games settles lawsuit against Samsung over app controls Swiss privacy tech firm Proton sues Apple in US over app store rules Apple must face consumer lawsuit over iCloud storage, US judge rules

India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says
India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says

Reuters

time2 minutes ago

  • Reuters

India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says

HYDERABAD July 23 (Reuters) - Dr Reddy's Laboratories ( opens new tab plans to launch a cheaper copycat version of Novo Nordisk's ( opens new tab blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday. Drugmakers are racing to get a share of the global obesity drug market, expected to generate around $150 billion in sales by the early 2030s, after Denmark-based Novo and its U.S. rival Eli Lilly (LLY.N), opens new tab saw extraordinary demand for their medicines. Dr Reddy's initially plans to launch the generic version of semaglutide - the active ingredient of Novo's Wegovy and diabetes medicine Ozempic - in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said. "U.S. and Europe will open later... (and) all the other Western markets will be open between 2029 to 2033," Israeli said a press conference to discuss the company's earnings. He expects the generic drug to generate 'hundreds of millions of dollars' in sales for the company. Semaglutide's patent is expected to expire in several countries next year, including in India in March. Novo Nordisk had sued Dr Reddy's in May alleging patent infringement of semaglutide, according to documents seen by Reuters. Dr Reddy's has filed relevant regulatory applications in all the countries it is planning to launch the generic version in, Israeli said. Other Indian drugmakers, including Cipla ( opens new tab, Lupin ( opens new tab, Biocon ( opens new tab, Sun Pharma ( opens new tab, also plan to launch these generic weight-loss drugs after Novo's and Lilly's success. Novo launched Wegovy in India last month, following Lilly's Mounjaro launch for weight-loss and diabetes management. The drugs belong to a class called GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer. Dr Reddy's also aims to launch 26 GLP-1 drugs within the next decade, Israeli said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store